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Abstract 
Background:  In a previously reported study, patients with regionally advanced melanoma were treated with neo-
adjuvant ipilimumab (ipi) (Tarhini in PLoS ONE 9(2): e87705, 3). Significant changes in circulating myeloid derived sup-
pressor cells (MDSC), regulatory T cells (Treg) and peptide specific type I CD4+ and CD8+ T cells were noted at week 6 
that correlated with clinical outcome. Characterization of antigen-specific effector T cell secreted cytokines may shed 
insights into ipi associated T cell activation and function.
Methods: Patients were treated with neoadjuvant ipi (10 mg/kg every 3 weeks ×2) administered intravenously 
before and after surgery. Peripheral blood mononuclear cells (PBMC) that were collected at baseline and week 6 (after 
ipi) were tested here. Each sample was divided into 5 groups and stimulated with controls or shared melanoma anti-
gen overlapping peptide pools (NY-ESO 1, gp-100, MART-1). Secreted cytokines, chemokines and growth factors were 
assessed using Luminex. Cytokine expression levels between the 3 antigen groups were compared using the Wilcox 
rank-sum test.
Results: Seventeen cytokines were differentially expressed with stimulation by each antigen at baseline (p value 
<0.05): IL1β, MIP1β, IL1RA, VEGF, IL13, IL17, MIP1α, GM-CSF, MCP1, IL5, IL2R, IL4, IL10, IFNγ, TNFα, IL8 and IL2. At week 
6, 15 cytokines were differentially expressed (p < 0.05): IL1β, VEGF, G-CSF, HGF, IL13, IL17, GM-CSF, MCP1, IL5, IL7, IL4, 
IL10, IFNγ, IL8 and IL2. Patients were later clustered based on cytokine expression levels at baseline and at week 6, and 
recurrence free survival (RFS) was compared. Clear differences in RFS were noted based on cytokine level clustering 
both at baseline and at week 6: Patients whose PBMCs secreted more cytokines in response to NY-ESO-1 showed a 
trend towards better RFS.
Conclusions: PBMCs of patients treated with ipi secreted significantly more cytokines, chemokines and growth 
factors in response to NY-ESO-1 than to gp-100 or MART-1. These cytokines belonged to different functional groups, 
including inflammatory, type 1, type 2 and regulatory, that warrant further study. Patients whose PBMCs secreted 
more cytokines (particularly in response to NY-ESO-1) tended to have better RFS, supporting further exploration in 
terms of therapeutic predictive value.
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Background
Melanoma continues to be a major public health prob-
lem in the United States (U.S.), with an estimated 76,380 
new cases diagnosed in 2016 and 10,130 deaths [1]. 
The treatment paradigm for patients with unresect-
able or metastatic disease has been revolutionized by 
the approval of novel targeted and immunotherapeu-
tic agents in recent years, but patients with resectable 
loco-regionally advanced melanoma continue to have 
poor outcomes. Indeed, the majority of patients with 
locoregional disease, including lymph node metastases, 
in transit metastases or satellite lesions will have recur-
rence after initial resection and develop metastatic dis-
ease [2, 3]. The prognosis for patients with stage I disease 
is excellent, with 5 year survival rates of 97% [4], though 
with increasing thickness, 5 year survival rates decrease. 
For example, patients with stage IIC disease have a 
5  year survival rate of 53% [4]. Outcomes for patients 
with stage III melanoma are overall worse, with 5  year 
survival of 78, 59, and 40% for stage IIIA, IIIB, and IIIC, 
respectively [4]. Recurrence risk for stage III melanoma 
also varies: 5-year overall recurrence free survival (RFS) 
for patients with stage IIIA, IIIB, and IIIC melanoma is 
63, 32, and 11%, respectively [5], and the key prognos-
tic factors are nodal involvement and primary features of 
the tumor [4]. The current standard of care for patients 
with locoregionally advanced disease is surgery followed 
by adjuvant high-dose interferon, pegylated interferon 
or ipilimumab [4, 6]. Because over half of patients with 
treated clinically detectable locoregional disease even-
tually develop metastases and die of their disease, there 
is an urgent need to develop novel approaches to the 
treatment of stage III melanoma, including neoadjuvant 
therapy.
In patients with locally advanced disease, neoadjuvant 
therapy has several potential advantages over adjuvant 
[3], and has been shown to improve survival outcomes 
in several malignancies, including esophageal, breast and 
bladder cancer [7–9]. Moreover, neoadjuvant treatment 
may facilitate surgery by shrinking tumors prior to sur-
gery, and may decrease the risk of metastasis by eradicat-
ing micrometastatic disease sooner rather than later [3].
We have previously reported a single-arm neoadjuvant 
phase II study in patients with stage IIIB-C melanoma. 
Patients received high dose ipilimumab (10  mg/kg IV 
q3  weeks ×4 doses total) bracketing definitive surgery 
[9]. Ipilimumab is a monoclonal antibody that binds to 
CTLA-4, which is up-regulated on T cells after activa-
tion and functions as a negative regulator of T cell acti-
vation. Median PFS was 15.5 months among 29 evaluable 
patients. In our previous analysis significant changes in 
circulating regulatory T cells (Treg), myeloid derived sup-
pressor cells (MDSC) and peptide specific type I CD4+ 
and CD8+ T cells were observed at 6  weeks that corre-
lated with clinical outcome [9]. A significant increase in 
circulating Treg was noted at week 6 compared to base-
line (p = 0.02), and increased Treg were associated with 
improved PFS (p  =  0.034). A significant decrease in 
peripheral MDSC was also noted, especially in the mono-
cytic gate (HLA-DR+/low, CD14+; p  <  0.0001), a key 
MDSC subset, and this was associated with improved PFS 
(p  =  0.03) [9]. Interestingly, and notably in the absence 
of any antigen specific stimulation, circulating CD4+ and 
CD8+ T cells specific for commonly expressed shared 
melanoma tumor antigens (gp-100, MART-1, NY-ESO-1) 
were increased in frequency after treatment. Taken 
together, these data suggest that ipilimumab favorably 
alters and positively modulates the circulating immune 
environment, and increases melanoma antigen-specific 
T cell responses. The characterization of T cell secreted 
cytokines may shed insights into ipilimumab associated 
T cell activation and function. Here, we report on differ-
ential T cell cytokine secretion at baseline and at week 6 
(following systemic therapy with ipilimumab) in response 
to melanoma lineage (gp-100, MART-1) and cancer tes-
tis (NY-ESO 1) antigen stimulation in 13 patients treated 
with ipilimumab in the neoadjuvant setting.
Methods
Patients and ethics
The characteristics of the total patient population were 
reported in the previously published study [15]. Char-
acteristics of the 13 tested here are shown in Table  1. 
The study was approved by the University of Pittsburgh 
Institutional Review Board (IRB; IRB# PRO09010033). 
All patients had a University of Pittsburgh IRB approved 
written informed consent obtained. The study was con-
ducted in accordance with the principles expressed in the 
Declaration of Helsinki. Eligible patients were 18  years 
or older and had clinically detectable locally and/or 
regionally advanced melanoma (cutaneous, mucosal or 
unknown primary).
Study design
Thirty patients were treated with neoadjuvant ipili-
mumab administered at 10  mg/kg intravenously (I.V.) 
on day 0 and day 21 followed by surgery at least 6 weeks 
later. Additional maintenance ipilimumab was offered 
following surgery, as we have previously reported [10]. 
Peripheral blood mononuclear cells (PBMC) samples col-
lected and cryopreserved at baseline and 6  weeks were 
used for this analysis from 13 patients who had either 
relapsed [3] or not [6] within the first year. PBMCs from 
each time point were thawed, aliquoted to a concentra-
tion of 1  ×  106 cells/ml in complete media, and each 
sample was then separated into 5 samples.
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Libraries of 15-mer peptides overlapping by 4 amino 
acids were constructed (Mimetopes, Minneapolis, MN) 
to measure CD4+  and CD8+  T cells specific to tumor 
antigens (Gp-100, MART-1, NY-ESO-1) in an HLA-
unrestricted fashion. PBMC were either [1] unstimulated 
(negative control), or stimulated with either [2] PMA/
inomycin (positive control), [3] a peptide pool consisting 
of 27 peptides from MART-1, [4] a peptide pool consist-
ing of 163 peptides from gp100, [5] a peptide pool con-
sisting of 43 peptides from NY-ESO-1. Samples were then 
incubated at 37 °C for 24 h. Samples were centrifuged and 
the supernatants saved in aliquots at −80 °C in a tempera-
ture controlled and monitored freezer. Samples did not 
thaw before testing. Supernatants were analyzed using 
the Multiplex Bead-based Luminex human 30-plex Assay 
cytokine plate, as per standard protocol, and run on a Bio-
Plex system (BioRad). The Cytokine Human 30-Plex Panel 
for the Luminex platform quantifies GM-CSF, IL-1β, IL-5, 
IL-4, IL-2, TNF-α, IL-6, RANTES, MIG, VEGF, HGF, EGF, 
IL-8, IL-17, MIP-1α, IL-10, G-CSF, MCP-1, IL-7, IL-15, 
IFN-α, IL-2R, IP-10, MIP-1β, Eotaxin, IL-1RA, IL-12 
(p40⁄p70) IL-13, FGF-Basic and IFN-γ (Additional file  1: 
Table S1). Assay controls included the kit standards for 
standard curves and Multiplex controls (R&D Systems).
Statistical methods
Expression level of cytokines in response to antigen 
stimulations were obtained by subtracting the corre-
sponding negative control value from measured values. 
If the measured value was under the detection limit or 
lower than the negative control value, it was assigned 
zero.
At baseline and week 6, Wilcox rank-sum test was used 
to identify cytokines that had different expression levels 
(unadjusted p value <0.05) when PBMCs were stimulated 
with NY-ESO-1 compared to the other two antigens. 
Expression levels of these cytokines under antigen stimu-
lation at each time point were plotted in a heatmap. For 
better visualization, non-zero values were truncated and 
logged.
Hierarchical clustering of patients was then performed 
using these differentially expressed cytokines as features 
at each time point. Due to sparsity of data, expression 
level of cytokines was dichotomized. Both Jaccard dis-
tance and 1-Phi coefficient were used as dissimilarity 
measure with eight different types of linkage to perform 
the clustering, and the patterns that consistently emerg-
ing were presented here.
Based on clustering results, patients were grouped into 
two clusters. Fisher’s exact test was applied to examine 
the association between cluster assignment and dichot-
omized RFS at 1 year. RFS of the two clusters were also 
compared using Kaplan–Meier plot and log-rank test. 
Because this is an exploratory study, p values were not 
adjusted for multiple testing.
Results
Patient information
Thirteen patients with available biospecimens were 
included in this analysis (Table 1). The median age was 
50 (range 40–81), with 10 males (77%) and 3 females 
(23%). The majority of patients (11; 84%) had a cutane-
ous primary, and 1 (8%) each had mucosal melanoma or 
melanoma of unknown primary. 10 patients (77%) were 
entirely asymptomatic, with an ECOG performance sta-
tus of 0, and 3 patients (23%) had an ECOG of 1. These 
patients were at high risk of recurrence, with 12 patients 
(92%) diagnosed as stage IIIC, and 1 patient (8%) had 
stage IIIB disease. 6 patients (46%) had a BRAFV600 
mutation. 2 patients (15%) were found to have NRASQ61 
mutation, and one had an NRASR73 mutation. 3 patients 
(23%) were BRAF/NRAS wild type, and one patient’s 
mutational status was unknown. All patients included in 
this analysis were treated with neoadjuvant ipilimumab 
bracketing definitive surgery, as previously reported.
Table 1 Patient demographics and  baseline disease char-
acteristics (N = 13 patients)
ECOG Eastern Cooperative Oncology Group
Variable No. of patients (%)
Age, years; median 50 (range 40–81)
Cutaneous primary 11 (84)
Mucosal primary 1 (8)
Unknown primary 1 (8)
Gender
 Female 3 (23)
 Male 10 (77)
Performance status (ECOG)
 0 10 (77)
 1 3 (23)
Stage
 IIIB 1 (8)
 IIIC 12 (92)
Tumor mutational status
 BRAFV600 6 (46)
 NRASQ61 2 (15)
 NRASR73 1 (8)
 BRAF/NRAS WT 3 (23)
 Unknown 1 (8)
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Cytokine profiles are differentially expressed at baseline 
in response to antigen stimulation
To determine the broad secreted protein expression pat-
tern of the shared melanoma antigen specific T cells in 
the circulation of these patients, and how they might be 
impacted by ipi, 30 cytokines, chemokines and growth 
factors in the supernatant of stimulated T cells were 
tested at baseline and at week 6 using the Human 30-Plex 
panel for Luminex. At baseline, prior to any treatment 
with ipilimumab, 17 cytokines were found to have higher 
expression levels when stimulated with NY-ESO-1 ver-
sus gp-100 or MART-1. On stimulation with NY-ESO1, 
expression of IL-1β, MIP1-β, IL1-RA, VEGF, IL-13, IL-17, 
MIP1-α, GM-CSF, MCP-1, IL-5, IL2-R, IL-4, IL-10, IFN-
γ, TNF-α, IL-8 and IL-2 was significantly higher (p value 
<0.05 for each) (Fig. 1).
Cytokine profiles are differentially expressed at week 6 
in response to antigen stimulation
At week 6 (after 2 cycles of ipilimumab), 15 cytokines 
were found to have higher expression when stimulated 
with NY-ESO-1 versus gp-100 or MART-1. On stimula-
tion with NY-ES0-1, expression of IL-1β, VEGF, G-CSF, 
HGF, IL-13, IL-17, GM-CSF, MCP-1, IL-5, IL-7, IL-4, 
IL-10, IFN-γ, IL-8 and IL-2 was significantly higher (p 
value <0.05 for each) (Fig. 2).
Cytokine expression levels at baseline and at week 6 
correlate with recurrence free survival (RFS)
Patients were clustered into two groups based on 
cytokine expression profile in response to NY-ESO-1 vs 
gp100 and MART-1. At baseline, patients 1, 5, 6, 7, 8, 9 
and 10 were in cluster 1, and patients 11, 17, 18, 20, 22 
and 28 were in cluster 2. The cluster result was correlated 
with RFS at 12 months. Poor RFS was defined as patients 
having died or relapsed within 1  year, and good RFS 
meant patients had not died or relapsed within 1  year. 
Though there was no statistically significant associa-
tion between cluster assignment and dichotomized RFS 
(p =  0.10), there was a trend towards improved RFS in 
cluster 1, where 5 out of 7 patients had good RFS. In clus-
ter 2, 5 out of 6 patients had poor RFS.
At week 6, patients 1, 5, 6, 7, 8, and 9 were in cluster 1, 
and patients 10, 11, 17, 18, 20, 22, and 28 were in cluster 
2. 4 out of 6 patients in cluster 1 had good RFS and 5 out 
of 7 patients in cluster 2 had bad RFS, however, there was 
no statistically significant association between cluster 
assignment and dichotomized RFS (p = 0.29).
We also observed differences in RFS based on cytokine 
level clustering both at baseline (p = 0.075) and at week 6 
(p = 0.082) (Fig. 3).
Discussion
Induction of potent antitumor T cell immunity is consid-
ered to be crucial for the therapeutic efficacy of immuno-
therapy. Here, we report on cytokine expression profiles 
from the PBMCs of 13 patients treated with neoadjuvant 
ipilimumab at baseline and at week six. We examined 
responses to two melanoma lineage (gp100, MART-1) 
and a cancer testis (NY-ESO-1) antigen, all commonly 
expressed by the majority of melanoma tumors [11–
13] and all known to be spontaneously immunogenic. 
We chose to assess expression levels of cytokines and 
chemokines with widely varied functions, and we show 
that at baseline (prior to treatment with ipilimumab), 
cytokine profiles are differentially expressed in response 
to antigen stimulation. We find that PBMC supernatants 
express 17 cytokines at higher levels when stimulated 
with NY-ESO-1 versus gp100 or MART-1, in line with 
the known spontaneous immunogenicity of NY-ESO-1 in 
eliciting CD4 and CD8 T cell responses [14] in addition 
to antibody responses. On stimulation with NY-ESO-1, 
expression of IL-1β, MIP1-β, IL1-RA, VEGF, IL-13, IL-17, 
MIP1-α, GM-CSF, MCP-1, IL-5, IL2-R, IL-4, IL-10, IFN-γ, 
TNF-α, IL-8 and IL-2 was significantly increased. Interest-
ingly, these cytokines fall into varying functional groups, 
including pro-inflammatory (IL-1β, MIP-1β, IL-17, IFN- 
γ, TNF-α and IL-8) and anti-inflammatory (IL-1RA, 
IL-10). We also find TH1 (IFN-γ, IL-2,) and TH2 (IL-4, 
IL-13) cytokines. These findings suggest that PBMCs of 
patients with advanced melanoma are polyfunctional, 
with expression of cytokines across varied pathways.
NY-ESO-1 is a member of the cancer testis antigen 
(CTA) family, a group of tumor-associated antigens that 
are expressed on multiple different tumor types, with 
expression in normal tissues restricted to placenta and 
testis [15]. NY-ESO-1 mRNA is expressed in 17–42% 
of melanomas [15–17], and it is thought to be the most 
immunogenic CTA [15]. Up to 50% of patients with 
advanced melanoma whose tumors express NY-ESO-1 
are seropositive for anti-NY-ESO-1 antibodies [18], and 
even in the absence of detectable antigen expression, 
NY-ESO-1 may induce NY-ESO-1 antibodies in 10% of 
patients [19]. NY-ESO-1 has also been shown to stimu-
late spontaneous and synchronized humoral and cell-
mediated immune responses. In one study, more than 
90% of patients with circulating anti-NY-ESO-1 antibod-
ies also had an NY-ESO-1-specific CD8+ T-cell response, 
whereas this effector T cell response was absent in 
patients without detectable anti-NY-ESO-1 antibody 
[20]. Therefore, many clinical trials of vaccines employ-
ing NY-ESO-1 are ongoing, with several already reported 
[21–24]. Thus, detection of multiple cytokines at elevated 
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expression levels in response to NY-ESO-1 antigen stim-
ulation suggests that patients with advanced disease (in 
our cohort, 92% had stage IIIC melanoma) have an NY-
ESO-1 specific immune response, though this is likely 
functionally dampened in the tumor microenvironment 
by immune checkpoints such as PD-1/PD-L1 [25] and 
CTLA-4 [26].
When PBMC cytokine expression levels were tested 
at week 6, after 2 cycles of ipilimumab, we find that 15 
cytokines have increased expression when stimulated 
with NY-ESO-1 versus gp-100 or MART-1. Specifically, 
expression of IL-1β, VEGF, G-CSF, HGF, IL-13, IL-17, 
GM-CSF, MCP-1, IL-5, IL-7, IL-4, IL-10, IFN-γ, IL-8 and 
IL-2 was significantly increased. Increased expression 































































Fig. 1 Heatmap of 17 analytes selected at Baseline: Expression pattern of 17 cytokines that respond differently to stimulation with NY-ESO-1 vs. 
gp-100 and MART-1 at baseline (p value <0.05): IL1β, MIP1β, IL1RA, VEGF, IL13, IL17, MIP1α, GM-CSF, MCP1, IL5, IL2R, IL4, IL10, IFN-γ, TNFα, IL8 and IL2. 
Patients were clustered into 2 groups: seven patients in cluster 1: 1, 5, 6, 7, 8, 9, and 10 tend to have better RFS and they also have higher cytokine 
expression when stimulated with NY-ESO-1
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in response to NY-ESO-1 versus gp-100 or MART-1 at 
week 6, as we saw at baseline, again suggests increased 
activated cell specificity for the NY-ESO-1 antigen. In 
addition, we again note cytokine and chemokine expres-
sion across multiple effector functions. Five proteins were 
elevated at baseline in response to NY-ESO-1 antigen, 
but not at week 6: IL-2R, IL-1RA, MIP-1α, MIP-1β, and 
TNF-α. At week 6, we noted an increase in G-CSF, IL-7 
and HGF, which had not been noted at baseline. Though 
difficult to draw conclusions from this small cohort, 
an increase in growth factors may indicate increased 
CD4 and CD8 T cell activation, though G-CSF is a key 

























































Fig. 2 Heatmap of 15 analytes selected Week 6: Expression pattern of 15 cytokines that respond differently to stimulation with NY-ESO-1 versus 
gp-100 and MART-1 at week 6 (p value <0.05): IL-1β, VEGF, G-CSF, HGF, IL-13, IL-17, GM-CSF, MCP-1, IL-5, IL-7, IL-4, IL-10, IFN-γ, IL-8 and IL-2 Patients 
were clustered into 2 groups: six patients in cluster 1: 1, 5, 6, 7, 8, and 9 tend to have better RFS and they also have higher cytokine expression when 
stimulated with NY-ESO-1
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modulator of MDSC [27, 28], and G-CSF expression has 
correlated with increased MDSC and worse overall sur-
vival in murine models [29].
We had previously reported that in 24 patients treated 
with neoadjuvant ipilimumab, for whom tumor tissue 
was available, CD8  +  tumor infiltrating lymphocytes 
were increased after treatment [10]. Furthermore, a sig-
nificant increase in circulating CD4+, CD8+ and T reg-
ulatory cells (Treg; CD4+ CD25+ Foxp3+) was noted at 
week 6, compared to baseline, and this correlated with 
improved PFS [10]. Numerous subsets of Treg have 
diverse functions in relation to the anti-tumor responses 
[30], and our findings of higher pro- and anti-inflamma-
tory cytokines in response to antigen stimulation with 
NY-ESO-1 after 6 weeks of treatment suggests that ipili-
mumab does not only function by a pro-inflammatory 
mechanism. Moreover, the pro-inflammatory response 
appears to be the most dominant, based on increases in 
several pro-inflammatory cytokines, including IL-1β, 
IL-6, MIP-1α, IL-17, IL-8, IL-2, TNF-α and IFN-γ, and 
this may be the mechanism leading to the clinical benefit 
seen in a subset of patients. In an exploratory analysis, we 
assessed the association between Treg and MDSC with 
our cytokine data, and no significant associations were 
found after adjusting for multiple testing, likely due to 
the small sample size that we are reporting on. We clus-
tered patients at baseline and at week 6 into two groups 
based on their cytokine expression profile. At baseline, 
seven patients were in cluster 1 and had higher cytokine 
expression when stimulated with NY-ESO-1, while 
six patients were in cluster 2. Poor RFS was defined as 
patients who had died or relapsed within 1 year, whereas 
patients with good RFS had not died or relapsed within 
1  year. Notably, the cluster into which patients were 
placed based on their cytokine expression profile was 
found to correlate with RFS at 12 months. While this did 
not reach statistical significance, there was a sharp trend 
towards improved RFS in cluster 1, where 5 of 7 patients 
had good RFS, whereas in cluster 2, 5 of 6 patients had 
poor RFS. These differences in RFS based on cytokine 
level clustering were noted both at baseline and at week 
6. This suggests that having higher cytokine expression in 
respond to NY-ESO-1 compared to gp-100 and MART-1 
may have some association with better RFS.
Our study has several limitations. The small cohort 
size limits the conclusions that can be drawn, and may 
be why we do not see a statistically significant differ-
ence when we compare RFS in cluster 1 versus cluster 
2. Furthermore, the cytokine expression levels were 
determined in supernatants of PBMC, clearly limit-
ing our ability to differentiate between expression pro-
files of specific cell subsets. Our earlier study testing 
intracellular cytokine expression confirmed that both 
CD4+ and CD8+ T cells produced IFN-γ, but many of 
these circulating proteins have other sources. To our 
knowledge, this is the first study to report on cytokine 
expression profiles from PBMCs of patients treated 
with ipilimumab. Furthermore, we compare levels at 
baseline and after 6 weeks of treatment. We show that 
at baseline, 17 cytokines are expressed at higher levels 
in response to NY-ESO-1 than in response to gp-100 or 
MART-1. We show that this difference is maintained 
after 6 weeks of treatment of ipilimumab. Importantly, 
we find that when patients are clustered into groups 
based on their cytokine expression profile, patients in 
cluster 1 had superior RFS compared to patients in clus-
ter 2. These findings warrant validation across a larger 
sample size, and it would also be important to deter-
mine if these differences are also seen in patients with 
metastatic melanoma who are treated with ipilimumab. 
If our findings persist in larger cohorts, this may help 
determine which patients are likely to derive RFS ben-
efit from ipilimumab.
Conclusion
Here, we report on cytokine expression profiles of 13 
patients treated with ipilimumab in the neoadjuvant setting. 
The supernatants collected from the PBMCs of patients 
treated with ipilimumab had increased cytokine expres-
sion when stimulated with NY-ESO-1 in comparison to 
gp-100 or MART-1. Interestingly, these cytokines belong 
to a broad functional range, including inflammatory, type 
1, type 2 and regulatory functions, and warrant further 












































Fig. 3 RFS by clustering; clustered by baseline cytokine levels: Panel 
a RFS in cluster 1 versus cluster 2, where patients are clustered by 
cytokine expression profile at baseline. Panel b RFS in cluster 1 versus 
cluster 2, where patients are clustered by cytokine expression profile 
at week 6
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study. Furthermore, patients whose PBMCs secreted more 
cytokines, most notably in response to NY-ESO-1, tended 
to have better RFS. This suggests that cytokine expression 
profiles may have predictive value in the context of CTLA-4 
blockade that warrant further exploration.
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